Dermata Therapeutics, Inc. - DRMA STOCK NEWS

Dermata Therapeutics announced Phase 2 trial results for DMT310, targeting moderate-to-severe rosacea, which did not meet primary endpoints. The treatment showed a 44% reduction in inflammatory lesions, but statistical significance wasn't achieved against placebo. Dermata plans to request an End of Phase 2 meeting with the FDA for DMT310 in acne treatment in Q1 2023. Despite the rosacea results, Dermata remains optimistic about DMT310's acne potential, citing significant effects in a prior study.

Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) reported progress in its clinical programs and financial results for Q3 2022. The company anticipates announcing topline results from the DMT310 Phase 2 trial for moderate-to-severe rosacea in December 2022 and plans to initiate the Phase 3 study for acne in 1H 2023. Financially, Dermata had $8.1 million in cash as of September 30, 2022, down from $10.8 million at year-end 2021. Research and development expenses rose to $1.6 million due to increased clinical activity, while general and administrative costs remained steady at $0.9 million.

Dermata Therapeutics, Inc. (Nasdaq:DRMA) announced that Gerry Proehl, its Chairman, President, and CEO, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The on-demand presentation will be accessible starting September 12 at 7:00 a.m. ET. Dermata, based in San Diego, focuses on medical and aesthetic skin conditions, with its lead candidate DMT310 targeting acne, rosacea, and psoriasis. A replay will be available for 90 days on the company's website.

Dermata Therapeutics (Nasdaq:DRMA), a clinical-stage biotechnology company, announced its participation in the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022. CEO Gerry Proehl will hold a fireside chat at 3:30 p.m. ET. The showcase recording will be available on Dermata’s Investor Relations website for six months after the event. Dermata focuses on medical and aesthetic skin treatments, with lead product candidate DMT310 targeting conditions like acne, rosacea, and psoriasis, derived from its Spongilla technology.

Dermata Therapeutics (Nasdaq: DRMA; DRMAW) announced its corporate progress and financial results for Q2 2022. The company closed a $5.0 million private placement, netting $4.3 million. It completed enrollment in its DMT310 Phase 2 study for rosacea, expecting topline results in the second half of 2022. As of June 30, 2022, Dermata held $10.6 million in cash, slightly down from $10.8 million at the end of 2021. R&D expenses rose to $1.6 million amid intensified clinical trial activities, while G&A expenses increased to $1.1 million.

Dermata Therapeutics (NASDAQ:DRMA) has completed enrollment in its Phase 2 trial of DMT310 for treating moderate-to-severe rosacea, affecting approximately 16 million patients in the U.S. This innovative treatment utilizes both mechanical and chemical mechanisms, and the results are expected to be announced in the second half of 2022. DMT310 previously showed a 62% reduction in inflammatory lesions during Phase 2 trials for acne. The trial involves 180 patients over 12 weeks, focusing on efficacy and safety, with primary endpoints including lesion counts and disease severity assessments.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) announced that Gerry Proehl, its Chairman and CEO, will present a company overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel, Miami Beach. During his presentation, he will discuss progress on the lead product candidate, DMT310, a weekly treatment for moderate-to-severe acne, and DMT410, a novel botulinum toxin delivery system. The on-demand presentation will be available starting May 24, 2022. For more details, visit Dermata's website.

Dermata Therapeutics (NASDAQ: DRMA; DRMAW) has completed a $5.0 million private placement to support clinical trials. The company is 90% enrolled in its Phase 2 trial for DMT310 targeting moderate-to-severe rosacea, with topline results expected in H2 2022. The additional funds will facilitate an end of Phase 2 meeting with FDA for DMT310's acne treatment and prepare for a Phase 3 program. As of March 31, 2022, Dermata reported $8.2 million in cash, a decrease from $10.8 million at the end of 2021, with operational expenses increasing significantly.

Dermata Therapeutics has successfully closed a private placement, raising $5.0 million through the sale of 3,773,585 shares of common stock and warrants. Each share was sold at a price of $1.325, with warrants exercisable over five years. The net proceeds will be allocated for working capital and corporate purposes. The transaction was facilitated by Maxim Group LLC as the placement agent. Dermata specializes in treatments for skin conditions and is developing its lead product candidate, DMT310, targeting acne and psoriasis.